On September 23, Axinn partner Aziz Burgy spoke at the ACI Summit on Biosimilars & Innovator Biologics Virtual Conference.

Aziz spoke on a panel entitled, "The Economics of Biosimilars: Considerations for Market Access, Sustainable Pricing and Reimbursement Policies." This panel analyzed the California legislation aimed at ending pay-for-delay in pharmaceutical patent infringement settlements. Speakers reviewed the implications of the House passed Lower Drug Costs Now Act. 

Click here for more information.